Drugs / HepavaxGene
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01349283 | May 2011 → Nov 2012 | hepatitis B virus infection | Crucell Holland BV | Completed | No outcome recorded |
| Phase 3 | NCT01289106 | Jan → Oct 2011 | HIV infectious disease | Chiang Mai University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02713620 Comparator | Jan 2015 → Jan 2016 | hepatitis B virus infection | Chiang Mai University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepavaxGene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01349283 ↗ |
| Known as | Hepavax-Gene TF | “Hepavax-Gene TF (thimerosal-free) vaccine” PMID 27753794 ↗ Jan 2017 |
| Modality | Vaccine | “three recombinant vaccine” PMID 31711528 ↗ Nov 2019 |
| Route | Intramuscular | “20 μg IM at months 0, 1, and 6” PMID 31711528 ↗ Nov 2019 |